The Early Cancer Detection Test-Lung Cancer Scotland study is designed to determine whether use of the Oncimmune blood test leads to earlier detection of lung cancer and can help to save lives in the long term.
Read MoreClinical data show the utility of Biocept’s liquid biopsy assay in therapeutic management of patients with non-small cell lung cancer.
Read More
The GeneStrat test by Biodesix reveals actionable NSCLC mutations, returning results within 72 hours.
Read More
Noninvasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy and months before detection of cancer progression with imaging.
Read More
Under a new agreement, Biodesix and Inivata will investigate the clinical utility of blood-based next-generation sequencing tests for patients with non-small cell lung cancer.
Read More